Tesamorelin: The FDA-Approved Peptide for Visceral Fat Reduction

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog and one of the few peptides in the growth hormone class with full FDA approval. It is approved to reduce excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy, and in that population large randomized trials showed meaningful reductions in organ-surrounding fat over six months.

That makes tesamorelin different from most of the peptides people read about online. It has labeled dosing, published safety data and phase 3 trials behind it. It also has clear limits, and understanding both sides is what allows a sensible conversation about whether it fits a particular patient.

What Tesamorelin Is and How It Works

Tesamorelin is a synthetic version of the full 44-amino-acid GHRH molecule, with a small chemical modification at one end that makes it resist rapid breakdown by enzymes. Here is the sequence of effects:

1. It binds GHRH receptors on the pituitary gland.
2. The pituitary releases growth hormone in natural pulses, with the body's normal feedback controls still in place.
3. The liver produces more IGF-1, which in studies typically stays within the normal range for age.
4. Growth hormone preferentially mobilizes visceral fat, the deep fat around the liver, intestines and other organs, more than fat under the skin.

Because it works through the body's own pituitary rather than replacing growth hormone directly, it is often described as a more physiologic way to raise growth hormone activity. For a broader look at this hormone system, see understanding IGF-1 and the tesamorelin entry in our peptide library.

Why Visceral Fat Matters

Not all body fat behaves the same way. Visceral fat is metabolically active and is associated with insulin resistance, fatty liver disease, abnormal lipids and cardiovascular risk. Two people with the same weight can carry very different amounts of it. This is one reason waist circumference and metabolic labs often tell me more than the scale does. See metabolic health markers every adult should track.

What the Tesamorelin Evidence Shows

Tesamorelin has the strongest human evidence of any peptide that acts on the growth hormone axis:

• Phase 3 trials in HIV lipodystrophy. Two randomized, placebo-controlled trials enrolling roughly 800 patients showed visceral fat reductions of about 15–18% compared with placebo over 26 weeks.
• Fatty liver in HIV. A randomized, double-blind trial published in 2019 found that tesamorelin reduced liver fat and was associated with less progression of fibrosis over one year in people with HIV and fatty liver disease.
• Cognition in older adults. A small 20-week randomized trial suggested improvements in executive function. This finding has not been replicated at scale and should be considered preliminary.

In the pivotal trials, visceral fat tended to return after tesamorelin was stopped. It is a treatment that works while it is used, not a permanent reset.

What Is Off-Label and Less Certain

Most interest in tesamorelin today is outside HIV, for general abdominal obesity, fatty liver disease or body composition. Those uses are off-label. The mechanism suggests it could help, and smaller studies are encouraging, but large trials in people without HIV are lacking. Patients deserve to know that difference before starting any medication.

It is also worth putting tesamorelin in context with other metabolic tools. GLP-1 medications such as semaglutide have much larger evidence bases for weight and cardiometabolic outcomes. For some patients, tesamorelin may be a complement; for many, it will not be the first choice.

Side Effects and Who Should Avoid It

Reported side effects in clinical trials include:

• Injection-site redness or itching
• Joint and muscle aches
• Swelling in the hands or feet
• Numbness or tingling in the hands
• A modest rise in blood glucose

Tesamorelin is not appropriate during pregnancy, in people with active cancer, or in those whose pituitary function has been disrupted by tumors, surgery or radiation. Because growth hormone can raise blood sugar, people with prediabetes or diabetes need closer monitoring.

How Tesamorelin Fits Into a Physician-Led Plan

At Laeeq M.D., I approach visceral fat as an internal medicine problem first. Before discussing tesamorelin, I want to know:

• Your metabolic baseline: fasting glucose, HbA1c, fasting insulin, lipid panel and liver enzymes
• Your growth hormone axis: IGF-1 and, when relevant, other pituitary hormones
• Your liver: whether imaging or elastography is warranted if fatty liver is suspected
• Your foundations: sleep, resistance training, protein intake, alcohol use and stress

If tesamorelin is reasonable, it is prescribed according to its labeling, with dosing individualized after evaluation, and we track IGF-1, glucose, lipids and waist measurements over time. Patients sometimes ask how it compares with other growth hormone secretagogues; CJC-1295 plus ipamorelin explains why those have weaker evidence and different regulatory standing.

Sources

• Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine, 2007. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
• Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 2019. https://pubmed.ncbi.nlm.nih.gov/31611038/

Book a Consultation

If you are concerned about visceral fat, fatty liver or body composition, a thorough evaluation is the right first step. Dr. Laeeq offers 60-minute consultations, virtually or in Reston, VA, for patients in Virginia, Maryland and other served states. You can book a consultation to review your labs and options.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.